Transdermal therapeutic system for the administration of peptides

A treatment system and drug delivery technology, applied to urinary system diseases, antineoplastic drugs, drug combinations, etc., can solve problems such as injuries, infections, and difficulties

Inactive Publication Date: 2012-08-15
LTS LOHMANN THERAPIE-SYST AG
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0015] Finally, difficulties can also arise during injection, mainly r

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Transdermal therapeutic system for the administration of peptides
  • Transdermal therapeutic system for the administration of peptides
  • Transdermal therapeutic system for the administration of peptides

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0104] Dissolve triptorelin acetate in aqueous acetate buffer solution (pH 5.0). Mannitol was added to the solution until it assumed a 3% mannitol concentration. After adding ethanol in polyvinylpyrrolidone (Kollidon 90F) and glycerin a substance is obtained from which a film of uniform thickness is made by coating and drying solvents (water, ethanol).

[0105] The table below gives the composition of the active substance-containing layer thus obtained in the dry state.

[0106] active substance layer

Quantity (unit g)

Quantity (unit %)

triptorelin acetate

3.39

16.95

Polyvinylpyrrolidone (dissolved in ethanol)

13.47

67.35

Glycerin

2.00

10.00

Sodium acetate (trihydrate)

0.48

2.40

Acetic acid

0.12

0.60

Mannitol

0.54

2.70

purified water

...

...

the sum

20.00

100

[0107] The layer thickness is about 40 μm....

example 2

[0112] Manufactured according to the pattern of Example 1, with the difference that the loading of triptorelin acetate corresponds to 0.1 mg / cm 2 , 0.2mg / cm 2 or 0.3mg / cm 2 .

example 3

[0114] The models of the transdermal therapeutic systems produced in Examples 1 and 2 with triptorelin acetate as active substance were tested for their permeability in a Franz cell diffusion cell. The results of this test are in Figure 4 is shown in , where bovine udder skin pretreated with laser ablation was used as a model diaphragm.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Molecular weightaaaaaaaaaa
Login to view more

Abstract

The invention relates to a transdermal therapeutic system (TTS), which is suited for the administration of a peptide to a patient through skin treated with ablation. Said transdermal therapeutic system comprises a back layer and an active substance-containing layer that contains at least one peptide and a carrier substance.

Description

technical field [0001] The subject of the present invention is a transdermal therapeutic system (TTS) for the molecular delivery of peptides and other macromolecules. Peptides which can be used as pharmaceutical active substances are particularly suitable here. Peptide hormones in particular belong to this class of substances. Background technique [0002] Transdermal therapeutic systems (TTS) have long been known as drug delivery forms. For the transdermal application of pharmaceutical active substances with TTS, the stratum corneum (SC), ie the outermost layer of the skin, in most cases constitutes an essential barrier to the permeability and passage speed of the pharmaceutical active substances. [0003] Peptides and proteins and other macromolecular molecules with a molecular weight above 500 Daltons (eg tacrolimus, heparin and many salts of betamethasone) are generally not transdermally absorbable due to their molecular size and their physicochemical properties. [0...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/70A61K38/09A61K38/11A61K38/095
CPCA61K38/095A61K9/7023A61K38/09A61K47/32A61K9/7084Y10T156/1089A61P13/00A61P15/00A61P15/08A61P3/00A61P35/00A61P7/02A61P7/04A61P7/12
Inventor M·霍斯特曼H·德兹坎S·维德斯贝格
Owner LTS LOHMANN THERAPIE-SYST AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap